Insider buying last 90 days
$7.50Min 1 open-market purchase
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 27 | PERCEPTIVE ADVISORS LLC director | Purchase | $7.50M |
From Form 4 filings, dated to when each was filed.
NASDAQ: IMTX
Immatics (IMTX) Stock Analysis & Forecast
Oct 12 close
$7.21−0.22 (−3.0%)
Gekko Brief
AI summaryOct 12 closeImmatics fell this week to a new 52-week low of $7.02 intraday, with shares highlighting HybridDIA research at a conference in Singapore even as the stock dropped 4.66% to EUR 6.34 on that day. Coverage also noted a "Moderate Buy" consensus rating from eight research firms with an average 12-month price target of $20.60, well above the then-current share price of $7.43, alongside commentary pointing to weak near and mid-term sentiment and elevated downside risk.
The stock closes at $7.21, down 3% on the day, and sits below both its 50-day average of $8.86 and 200-day average of $9.77, with the 50-day below the 200-day. The GekkoIndex reads 72.4, placing IMTX in the Buying zone. Gekko Fair Value stands at $11.88, putting the current price 39.3% below that level.
The next earnings date falls on 17 November 2026, before the open, which is 36 days away and outside a typical 20-trading-day holding window; the prior report on 18 August 2026 showed an EPS of -0.53 against an estimate of -0.48, with a 0% reaction, and 4 beats in the last 8 quarters. Over the last 90 days, smart-money activity includes 1 open-market insider purchase valued at $7,499,991. Seasonality over the next 20 trading days has averaged -8.4% across 5 years, rising in only 1 of them. Analyst coverage shows 5 firms rating the stock buy, with a consensus target of $17.63 and consensus upside of 144.5%.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Immatics price vs fair value
Close $7.21200-day averageGekko Fair Value $11.88
Immatics quick facts
- Market cap
- $966.8M
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.87
- Revenue, TTM
- $41.70M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.36
- Volume
- 750,362 avg 859,673
- 1-year return
- −33.9%
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±9.6%
- 50-day average
- $8.86
- 200-day average
- $9.77
- Next earnings
- Nov 17 before open
- Shares outstanding
- 152.2M
Immatics swing-trade checklist
Immatics scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $7.21 is below the 50-day ($8.86) and 200-day ($9.77) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
72.4, Buying
Reading 72.4 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
39.3% below
Price is 39.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 1 open-market insider purchase.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 17, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−8.4% on average
From this point in the calendar, the next 20 trading days averaged −8.4% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Immatics stock chart and price history
Immatics closed at $7.21 on Oct 12, 2026, −33.9% over the past year, inside a 52-week range of $7.02 to $12.41.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −18.0%
- 3 months
- −22.9%
- 6 months
- −33.7%
- 1 year
- −33.9%
The full IMTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IMTX in Gekko
Follow Immatics through every session
Put IMTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IMTX in GekkoFree for 7 days. No credit card required.
About Immatics
Immatics works on cancer treatment, developing immunotherapies built around T-cell receptors that target solid tumors. Its work is still in clinical and preclinical stages, mainly focused on the United States market, and it pursues two main approaches: adoptive cell therapies and TCR Bispecific antibody-like treatments. Among its best-known programs are the ACTengine candidates, including IMA201, IMA202, and IMA203, each aimed at different tumor-associated antigens across various solid tumor types, along with earlier-stage projects like IMA204 and its Bispecifics pipeline such as IMA401 and IMA402.
The company advances its pipeline partly through partnerships with larger organizations, including GlaxoSmithKline, MD Anderson Cancer Center, Celgene Switzerland, and Genmab, each supporting different aspects of its cell therapy and bispecific immunotherapy research. These collaborations span various cancer indications and contribute to Immatics' efforts to bring multiple candidates through development simultaneously.
Immatics is headquartered in Tübingen, Germany. Its shares are listed on the NASDAQ under the ticker IMTX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- immatics.com
Immatics GekkoIndex: the smart money zone
Immatics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 72.4, in the Buying zone, up 2.5 points over five sessions.
72.4Buying
Up 2.5 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 54 | +1.4% | −5.4% | ||
| Accumulation | 270 | −0.5% | +0.7% | ||
| Neutral | 338 | 0.0% | +1.0% | ||
| Distribution | 19 | +2.4% | −3.0% | ||
| Selling | 1 | Too few readings yet | |||
Average IMTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the IMTX price, zone by zone.Track IMTX in Gekko
Is Immatics stock overvalued? Gekko Fair Value
Immatics trades 39.3% below Gekko Fair Value of $11.88, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Immatics shares are worth, recalculated every trading day.
$11.88
Gekko Fair Value, Oct 10, 2026
39.3% Undervalued
At the end of Aug 2026 the price was 35.4% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open IMTX in Gekko
Immatics insider and Congress trading
Insiders filed 1 open-market purchase in Immatics worth $7.50M, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IMTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IMTX, plotted on the chart in Gekko.Open IMTX in Gekko
Immatics earnings: next date and track record
Immatics reports on Nov 17, 2026, before the open (36 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 17, 2026
Expected before the open, 36 days away
- EPS estimate
- −$0.50
- Revenue estimate
- $12.32M
4 of 8reports beat the EPS estimate
±3.2%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 18, 2026 | −$0.53 est −$0.48 | $11.88M est $11.90M | 0.0% |
| May 12, 2026 | −$0.50 est −$0.42 | $8.78M est $9.79M | −6.5% |
| Mar 5, 2026 | −$0.34 est −$0.48 | $22.32M est $11.26M | −3.1% |
| Nov 17, 2025 | −$0.49 est −$0.44 | $6.08M est $10.71M | +1.2% |
| Aug 13, 2025 | −$0.66 est −$0.38 | $5.58M est $12.53M | −8.1% |
| May 13, 2025 | −$0.35 est −$0.39 | $20.37M est $13.51M | 0.0% |
| Mar 27, 2025 | $0.48 est −$0.33 | $58.25M est $23.72M | +2.2% |
| Nov 18, 2024 | −$0.12 est −$0.27 | $55.45M est $16.16M | −4.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Immatics stock forecast and analyst price targets
Analysts’ average 12-month price target for Immatics is $17.63, +144.5% from the last close, from 5 firms rating the stock in the last 90 days.
$17.63consensus 12-month target, +144.5% from the last close
Now $7.21Avg $17.63
Low $11.80High $25
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 25 | Jefferies | $17 | +135.8% |
| Aug 20 | Mizuho Securities | $25 | +246.7% |
| Aug 18 | TD Cowen | — | — |
| Aug 18 | Bank of America Securities | $17 | +135.8% |
| Aug 18 | Goldman Sachs | $11.80 | +63.7% |
−5.4%average 20-day move after past Buying readings
−8.4%average move over the next 20 trading days in the last 5 years
±6.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Immatics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Immatics averaged −8.4% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.7% | 2 of 5 |
| Next 10 trading days | −8.4% | 0 of 5 |
| Next 15 trading days | −6.5% | 2 of 5 |
| Next 20 trading days | −8.4% | 1 of 5 |
| Next 30 trading days | −14.5% | 0 of 5 |
For scale, IMTX’s typical 20-trading-day move in either direction is about 9.6%.
Immatics market cap and key statistics
Immatics’s market cap is $966.8M and revenue of $41.70M over the last twelve months.
Valuation
- Market cap
- $966.8M
- EPS, TTM
- −$1.87
- Gekko Fair Value
- $11.88
Trading
- Volume
- 750,362
- Avg volume, 20 days
- 859,673
- 52-week high
- $12.41
- 52-week low
- $7.02
- Shares outstanding
- 152.2M
Financials
- Revenue, TTM
- $41.70M
- Profit margin
- 0%
- Return on equity
- -47.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.36
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±9.6%
Immatics stock news this week
Coverage of Immatics this week reads negative: 0 positive, 1 neutral and 2 negative headlines.
- Immatics N.V. (NASDAQ:IMTX) Stock Has Consensus Target Price of $20.60 According to BrokeragesMarketBeat, Oct 10
- Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial ContrastDefense World, Oct 9
- Immatics (NASDAQ:IMTX) Reaches New 1-Year Low – Here’s WhyDefense World, Oct 9
- Immatics highlights HybridDIA research. Immatics stock falls 4.66 percentAD HOC NEWS, Oct 8
- (IMTX) and the Role of Price-Sensitive AllocationsStock Traders Daily, Oct 7
Immatics peers
Immatics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Immatics stock FAQ
What is Immatics’s market cap?
Immatics’s market cap is $966.8M at the Oct 12, 2026 close of $7.21, with 152.2M shares outstanding.
What is the Immatics stock forecast?
The consensus analyst 12-month price target for Immatics is $17.63, +144.5% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Immatics stock overvalued or undervalued?
On Gekko’s estimate Immatics is undervalued: the Oct 12, 2026 close of $7.21 is 39.3% below Gekko Fair Value of $11.88. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Immatics report earnings next?
Immatics is expected to report on Nov 17, 2026, before the market opens (36 days away). Analysts expect earnings of −$0.50 per share on revenue of $12.32M. Immatics beat the earnings estimate in 4 of its last 8 reports, moving 3.2% on average across the report.
What is Immatics’s 52-week high and low?
Immatics’s 52-week high is $12.41 and its 52-week low is $7.02; it closed at $7.21 on Oct 12, 2026, −33.9% over the past year. Over the last five years the shares peaked at $14.90 on Nov 1, 2021.
Is Immatics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Immatics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.